Yes - These Sections Are Consistent with Choriocarcinoma of the Ovary

Low-Power View (IMG_1527) - Architectural Features

• A highly disorganized, destructive growth pattern with no chorionic villi - this is the single most important low-power finding. Villi are absent in choriocarcinoma, distinguishing it from hydatidiform mole.
• Extensive lakes of hemorrhage interspersed between cords and nests of atypical cells. This hemorrhagic pattern reflects direct vascular invasion by tumor cells that erode host blood vessels without forming a fibrovascular stroma.
• A plexiform/anastomosing pattern: sheets and cords of tumor cells wrap around blood-filled spaces.
• On the left margin, fibromuscular wall (ovarian capsule) is being invaded by the tumor.
• Absence of intrinsic stroma: the tumor nests have no internal supporting connective tissue - cells depend entirely on invaded host vessels for nutrients.
• Coagulative necrosis: amorphous eosinophilic debris in areas away from viable tumor cells, typical of rapidly growing malignancies.

High-Power View (IMG_1530) - The Two Cell Types

1. Cytotrophoblasts (CT)

2. Syncytiotrophoblasts (ST)

The Classic Dimorphic Pattern - The Diagnostic Key

Why This Is Ovarian Choriocarcinoma (Not Gestational/Metastatic)

Key Ancillary Tests to Order

1. Serum beta-hCG - markedly elevated (secreted by syncytiotrophoblasts); critical for monitoring
2. IHC panel:
   • hCG - diffuse positivity in syncytiotrophoblasts
   • CK (AE1/AE3) - positive in both cell types
   • PLAP - may be positive
   • Inhibin - negative (helps rule out sex cord-stromal tumor)
   • EMA - positive
3. Molecular/genotyping - to distinguish gestational (paternal alleles present) vs. non-gestational (no paternal contribution) - this changes prognosis and treatment

Reference Images from Textbook for Comparison

Summary

1. Biphasic trophoblastic differentiation - cytotrophoblasts + syncytiotrophoblasts
2. Absence of chorionic villi
3. Extensive hemorrhage and necrosis
4. Destructive, invasive growth without intrinsic stroma
5. Abundant mitoses with nuclear pleomorphism

🎓 Choriocarcinoma of the Ovary - Complete Teaching Note

1. INTRODUCTION & CLASSIFICATION

Ovarian Germ Cell Tumors
├── Dysgerminoma (most common malignant GCT)
├── Yolk Sac Tumor (Endodermal Sinus Tumor) → AFP
├── Immature Teratoma
├── Choriocarcinoma ← we are here → hCG
├── Embryonal Carcinoma
├── Polyembryoma
└── Mixed Germ Cell Tumor

• Oogonia → Dysgerminoma
• Extraembryonic yolk sac → Yolk sac tumor
• Placental tissue → Choriocarcinoma
• Multiple germ layers → Teratoma

2. THE TWO TYPES OF OVARIAN CHORIOCARCINOMA

The distinction matters enormously: misclassifying a gestational choriocarcinoma as non-gestational would deny the patient a near-curative treatment.

3. INCIDENCE & EPIDEMIOLOGY

• Pure non-gestational ovarian choriocarcinoma is extremely rare - only a few hundred cases in world literature
• Most "ovarian choriocarcinomas" are actually metastases from uterine/gestational choriocarcinoma, or occur as a component of a mixed germ cell tumor
• In mixed germ cell tumors, choriocarcinoma is found in ~20% of cases (combined with dysgerminoma, EST, immature teratoma)
• Pure form: typically presents in girls < 20 years, often pre-menarchal
• Age of your case (39F): relatively unusual for pure primary - needs gestational origin exclusion

4. PATHOGENESIS

Primordial Germ Cell
        ↓
Malignant transformation
        ↓
Differentiates along trophoblastic/extraembryonic pathway
        ↓
Produces BOTH cytotrophoblasts AND syncytiotrophoblasts
        ↓
Syncytiotrophoblasts secrete β-hCG
        ↓
Elevated serum hCG → clinical features

5. GROSS PATHOLOGY

• Soft, fleshy, yellow-white tumor
• Extensive hemorrhage (dark red-brown areas)
• Large pale areas of necrosis
• Typically unilateral
• Can be large; the primary tumor may paradoxically be small even with widespread metastases (especially in testicular counterpart)

6. HISTOPATHOLOGY - THE DIAGNOSTIC CORE

The Golden Rule: Dimorphic Trophoblastic Pattern + No Villi

Cell Type 1: Cytotrophoblasts (CT)

• Small to medium polygonal cells
• Mononuclear - single large vesicular nucleus
• Prominent nucleoli
• Clear to pale eosinophilic cytoplasm with distinct cell borders
• Abundant mitoses (these are the proliferating cells)
• Arranged in cohesive nests and sheets - form the "inner" core
• Represent the stem/progenitor trophoblast - analogous to Langhans layer of placenta

Cell Type 2: Syncytiotrophoblasts (ST)

• Large to giant cells
• Multinucleated - 3 to 30+ nuclei in shared cytoplasm
• Nuclei are hyperchromatic, pleomorphic, irregular, crowded and overlapping
• Voluminous, deeply eosinophilic to amphophilic cytoplasm
• Irregular smudged outer borders - reflects cytoplasmic fusion
• Do NOT divide - no mitoses in ST themselves
• Cap and wrap around the CT nests - "peripheral" or "capping" arrangement
• Secrete β-hCG - the source of the hormonal manifestations

The Relationship Between CT and ST

Cytotrophoblasts (proliferate) → fuse → Syncytiotrophoblasts (functional, secrete hCG)
     ↑ mitotically active                      ↑ post-mitotic, non-dividing
     ↑ inner layer                             ↑ outer/capping layer

Other Key Histological Features

7. IMMUNOHISTOCHEMISTRY

8. CLINICAL FEATURES

Symptoms

• Abdominal pain / pelvic mass - most common presentation
• Irregular uterine bleeding - if uterus is present
• Isosexual precocious puberty - in ~50% of pre-menarchal girls with high hCG (hCG cross-reacts with LH receptor → stimulates estrogen production → early breast development, vaginal bleeding, pubic hair)
• Amenorrhea in reproductive age
• Hemoptysis if pulmonary metastases

Tumor Markers

• β-hCG: markedly elevated - the most important marker for diagnosis, staging, and monitoring
• AFP: negative (if elevated → think yolk sac tumor component → likely mixed GCT)

9. METASTATIC PATTERN

Lymphatic spread is uncommon - this tumor travels through blood.

10. DIFFERENTIAL DIAGNOSIS

11. STAGING (FIGO)

• Stage I: Confined to ovary/ovaries
• Stage II: Pelvic extension
• Stage III: Peritoneal/retroperitoneal nodes
• Stage IV: Distant metastases (pleural, hepatic parenchyma, brain)

12. TREATMENT

Surgery

• Unilateral salpingo-oophorectomy with frozen section - fertility-preserving if possible (important given young age of most patients)
• Staging laparotomy; debulk gross metastases
• Hysterectomy + contralateral oophorectomy generally NOT needed unless disease demands it

Chemotherapy

• BEP (Bleomycin + Etoposide + Cisplatin) - first-line for ovarian germ cell tumors; 3-4 cycles
• MAC (Methotrexate + Actinomycin D + Cyclophosphamide) - used in gestational form; some reports of complete response in non-gestational too

• EMA-CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide, Oncovin/Vincristine) - near 100% cure
• Single-agent methotrexate or actinomycin D for low-risk disease

Key difference: Gestational type responds dramatically to chemotherapy (near 100% remission). Non-gestational ovarian type is relatively chemoresistant and has a poor prognosis.

13. PROGNOSIS

14. WORKUP SUMMARY (What to Order)

Suspected Ovarian Choriocarcinoma
│
├── SERUM: β-hCG (diagnostic + monitor), AFP, LDH, CA-125
├── IMAGING: CT chest/abdomen/pelvis (staging), MRI pelvis, CXR
├── HISTOLOGY: Frozen section → paraffin H&E
├── IHC: β-hCG, CK, AFP, inhibin, OCT3/4, CD30
├── MOLECULAR: STR genotyping to distinguish gestational vs non-gestational
└── ONCOLOGY REFERRAL: Urgent (aggressive tumor)

15. QUICK MEMORY AIDS

🎓 Fibroadenoma with Lactational Change in the Vulva - Complete Teaching Note

1. UNDERSTANDING THE FOUNDATION: What Is the Tissue of Origin?

What are AGMLGs?

• The same morphology as breast lobular units (ductal + acinar structures)
• Identical immunohistochemical profile (ER+, PR+, GCDFP-15+, GATA3+, p63+ myoepithelium)
• The same hormonal responsiveness (enlarge during pregnancy, involute after menopause)
• The same capacity to develop all the same lesions as the breast

The Embryological Basis: The Milk Line

                  Axilla
                    ↓
                  Breast (normal)
                    ↓
              Inframammary region
                    ↓
                 Abdomen
                    ↓
                  Groin
                    ↓
             VULVA ← ← ← ← (AGMLG territory)
                    ↓
                 Perineum

2. FIBROADENOMA OF THE VULVA - DEFINITION

1. AGMLG tissue (most current explanation), OR
2. Ectopic breast tissue along the milk line that persisted in the vulva

3. EPIDEMIOLOGY & CLINICAL FEATURES

4. GROSS PATHOLOGY

• Well-circumscribed, rubbery, gray-white nodule
• Bulges above cut surface when sectioned
• Slit-like spaces visible on cut surface (represents compressed glandular elements)
• No hemorrhage, necrosis, or infiltrative borders

5. HISTOPATHOLOGY - STANDARD FIBROADENOMA

Basic Biphasic Architecture

FIBROADENOMA = EPITHELIAL component + STROMAL component

• Branching glandular/ductal structures
• Inner epithelial layer + outer myoepithelial layer (bilayered)
• Luminal cells are cuboidal to columnar, uniform, no atypia
• Nuclei: small, round, regular with inconspicuous nucleoli

• Delicate, myxoid to fibrous stroma resembling normal intralobular stroma
• Hypocellular (paucicellular) - this is a key distinguishing feature from phyllodes tumor
• No stromal atypia, no significant mitoses

Two Growth Patterns

6. LACTATIONAL CHANGE - THE SPECIAL FEATURE

What Is Lactational Change?

Histological Features of Lactational Change:

Schematic of Lactational Change:

Normal epithelial cell:
[Nucleus in center] [Pale cytoplasm]

With Lactational Change:
[Nucleus pushed to base ↓] [Vacuolated cytoplasm with fat globules ↑↑↑]
                            [Secretion into lumen →]

Why Does This Happen in the Vulva?

• Enlarge rapidly during pregnancy - raising clinical suspicion of malignancy
• Become tender or fluctuant during lactation
• Spontaneously regress after delivery/cessation of breastfeeding

7. LACTATIONAL CHANGE vs. LACTATING ADENOMA - KEY DISTINCTION

Practical pearl: "Other lesions of anogenital mammary-like glands can exhibit lactational changes such as a fibroadenoma." - Basicmedical Key (citing Kazakov)

8. IMMUNOHISTOCHEMISTRY

9. DIFFERENTIAL DIAGNOSIS

10. TREATMENT & PROGNOSIS

• Simple (complete) surgical excision - curative; en-bloc excision is preferred
• Recurrence: rare with complete excision; incomplete excision or hormone exposure (pregnancy) can drive recurrence
• Long-term surveillance: warranted because:
  • Hormonal re-stimulation (future pregnancies) can cause recurrence
  • Small risk of malignant transformation (same as breast fibroadenoma - slightly elevated if complex)
• Prognosis: Excellent - benign behavior identical to breast fibroadenoma
• Fertility preservation: surgery is straightforward; no impact on fertility or breastfeeding from the contralateral breast

11. FULL SPECTRUM OF AGMLG LESIONS (Context)

BENIGN                          BORDERLINE              MALIGNANT
├── Fibroadenoma                ├── Phyllodes tumor      ├── Invasive carcinoma
├── Lactating adenoma           │   (borderline)         ├── DCIS
├── Hidradenoma papilliferum                             ├── Phyllodes (malignant)
├── Sclerosing adenosis                                  ├── Hidradenocarcinoma papilliferum
├── Fibrocystic change                                   └── Extramammary Paget disease
├── PASH
└── Intraductal papilloma

12. QUICK MEMORY FRAMEWORK

FIBROADENOMA VULVA = "Breast tumor in wrong address"

Origin:   Anogenital Mammary-Like Glands (AGMLG) - normally present in vulva
Histology: BIPHASIC = glands (ER+, bilayered) + fibrous stroma
Lactational change = glands + cytoplasmic vacuoles + secretion + maintained stroma
IHC:      ER+, PR+, GATA3+, p63+ myoepithelium
Clinically: Painless mobile nodule in labia majora, reproductive age woman
Pregnancy: Rapid enlargement (do NOT panic - benign)
Treatment: Excise completely; follow up
Distinguish from phyllodes: stroma cellularity + mitoses
Distinguish from lactating adenoma: biphasic vs. purely secretory